Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 2
2009 1
2010 1
2011 2
2012 5
2013 3
2014 1
2015 4
2016 2
2017 2
2018 1
2019 2
2020 5
2021 5
2022 7
2023 3
2024 2
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: pazgan simon m. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Qin S, Gu S, Chan SL, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Xu L, Yuan X, Li D, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Du J, Shi W, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: pazgan simon m. Lancet Oncol. 2025 Dec;26(12):1598-1611. doi: 10.1016/S1470-2045(25)00543-1. Lancet Oncol. 2025. PMID: 41308676 Clinical Trial.
Implementation of the web-based calculator estimating odds ratio of severe COVID-19 for unvaccinated individuals in a country with high coronavirus-related death toll.
Kwasniewski M, Korotko U, Chwialkowska K, Niemira M, Jaroszewicz J, Sobala-Szczygiel B, Puzanowska B, Moniuszko-Malinowska A, Pancewicz S, Parfieniuk-Kowerda A, Martonik D, Zarebska-Michaluk D, Simon K, Pazgan-Simon M, Mozer-Lisewska I, Bura M, Adamek A, Tomasiewicz K, Pawłowska M, Piekarska A, Berkan-Kawinska A, Horban A, Kowalska J, Podlasin R, Wasilewski P, Azzadin A, Czuczwar M, Borys M, Piwowarczyk P, Czaban S, Bogocz J, Ochab M, Kruk A, Uszok S, Bielska A, Szałkowska A, Raczkowska J, Sokołowska G, Chorostowska-Wynimko J, Jezela-Stanek A, Rozy A, Lechowicz U, Połowianiuk U, Tycinska A, Grubczak K, Starosz A, Izdebska W, Krzemiński TF, Bousqet J, Franchini G, Hadlock J, Kretowski A, Akdis M, Akdis CA, Sokolowska M, Eljaszewicz A, Flisiak R, Moniuszko M. Kwasniewski M, et al. Among authors: pazgan simon m. Allergy. 2023 Jan;78(1):311-314. doi: 10.1111/all.15524. Epub 2022 Sep 29. Allergy. 2023. PMID: 36129377 Free PMC article. No abstract available.
53 results